Extended Data Fig. 2: Cholestyramine cannot reverse B. vulgatus-induced PCOS-like phenotype.
a and b, Cholestyramine reduces the content of bile acids in mouse intestinal epithelium (a) and serum (b). (a) CA, P = 2.32 × 10−7; α-MCA, P = 0.000008; TCA, P = 2.85 × 10−7. (b) TUDCA, P = 0.000016. c-j, Cholestyramine treatment mice were gavaged with wild type B. vulgatus (Bv) or PBS (Vehicle) for three weeks. c, Quantitative analysis of cystic follicles in the ovaries. d, Levels of testosterone in serum. e, Levels of LH in serum. f, Glucose tolerance test (GTT) (15min: ***P = 0.0007; 30min: *P = 0.0249; *P = 0.0183; *compared with the vehicle + Cholestyramine). g, Area under the curve (AUC) of GTT. h, Insulin tolerance test (ITT) (15min: *P = 0.0152; 30min: **P = 0.0087; *compared with the vehicle + Cholestyramine). i, The levels of fasting glucose in serum. j, The level of insulin in serum. All data are presented as the mean ± s.e.m. (a, b, c) n = 5/group. (d-j) n = 6/group. In a, b, d-g, i, j, the P values were determined by two-tailed Student’s t-test. In c, h, the P values were determined by two-tailed Mann–Whitney U-test.
